{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-323940","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2026-07-29T20:35:16+00:00","discovered_at":"2026-07-29T20:36:00.370895+00:00","generated_at":"2026-07-29T20:36:13.846926+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dyne Therapeutics reports Q2 2026 net loss of $178.6M; BLA for z-rostudirsen accepted with Priority Review","bullets":["Net loss of $178.6M ($1.08 per share) vs $110.9M ($0.97) in Q2 2025.","BLA for z-rostudirsen (exon 51 DMD) accepted by FDA with Priority Review; PDUFA date Jan 21, 2027.","Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for z-basivarsen in DM1; topline data Q1 2027.","IND cleared for DYNE-302 in FSHD; Phase 1 trial planned.","Cash, cash equivalents and marketable securities $898.5M as of June 30, 2026; expected cash runway into Q2 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-323940","json":"https://secwatch.observer/filing/0001193125-26-323940.json","markdown":"https://secwatch.observer/filing/0001193125-26-323940.md","text":"https://secwatch.observer/filing/0001193125-26-323940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/0001193125-26-323940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:36:13.846926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}